Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT01881503
NA

Expanded Access Study of HBOC-201 (Hemopure) for the Treatment of Life-Threatening Anemia

Sponsor: Englewood Hospital and Medical Center

View on ClinicalTrials.gov

Summary

The purpose of this expanded access study is to be able to provide treatment with HBOC-201 to patients with life-threatening anemia for whom blood is not an option. HBOC-201 is not FDA approved for use in the United States, but is approved as an oxygen carrier in South Africa and Russia.

Official title: Expanded Access Protocol for the Treatment Use of HBOC-201

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2013-10

Completion Date

2026-12

Last Updated

2025-04-13

Healthy Volunteers

No

Conditions

Interventions

BIOLOGICAL

HBOC-201

HBOC-201 is purified, cross-linked, acellular bovine hemoglobin (Hb) in a modified lactated Ringer's solution.

Locations (1)

Englewood Hospital and Medical Center

Englewood, New Jersey, United States